United Kingdom Archives

News and Trends 16 Jul 2018

CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage

Researchers at the Wellcome Trust Sanger Institute in the UK have found that gene editing with CRISPR-Cas9 can cause significantly more off-target damage to the DNA than previously thought. Published today in Nature Biotechnology, the study is the first to look at unexpected DNA changes caused by CRISPR across large regions of the genome. […]

July 16, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 2 Jul 2018

New Blood Test Brings Cheaper Hepatitis B Diagnosis

European and African researchers are developing a hepatitis B blood test that could help identify patients in Africa’s poorest regions who need immediate treatment. While treatments for hepatitis B are now available at a low cost, managing treatments effectively is still a challenge in Africa. This is because some patients who are infected with the […]

July 2, 2018 - 2 minutesmins - By Alexander Burik

Best in Biotech 2 Jul 2018

13 Biotech Leaders You Should Know in the UK’s Golden Triangle

After listing the top biotech leaders in Munich, we investigated the ‘golden triangle’ in the UK to find out who are the most influential biotech leaders there. The so-called ‘golden triangle’ of universities in Oxford, Cambridge and London concentrates a large percentage of the UK’s biotech research and industry, ranging from big pharma, like AstraZeneca and GSK, […]

July 2, 2018 - 8 minutesmins - By Philip Hemme

Duchenne muscular dystrophy Summit Therapeutics

News and Trends 28 Jun 2018

Muscular Dystrophy Drug Fails in Phase 2 Trial

The stock of Summit Therapeutics has plunged by 80% after announcing that its drug candidate for Duchenne muscular dystrophy failed to meet the primary and secondary endpoints of a Phase II clinical trial. Duchenne muscular dystrophy is a genetic disease that causes progressive muscle deterioration in children born with the disease. The British-American company Summit […]

June 28, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

gw pharmaceuticals fda epidiolex cannabinoid epilepsy

News and Trends 26 Jun 2018

Update: The FDA Approves First Cannabinoid Treatment for Epilepsy

Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […]

June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Jun 2018

A Biodegradable Plaster Could Help us Treat Mouth Ulcers

British researchers and a Danish biotech have joined forces to develop a polymer patch that can treat mouth ulcer patients with long-term steroid release and make the wound-healing process faster. Dermtreat, based in Copenhagen, and researchers from the University of Sheffield’s School of Clinical Dentistry in the UK made a patch from polymers that stick […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 22 Jun 2018

Next-Generation CAR-T Company Raises €130M on NASDAQ IPO

London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […]

June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jun 2018

Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World

Researchers at the University of Edinburgh have genetically engineered pigs that are resistant to a common disease that has exorbitant costs to the livestock industry. Researchers at the University of Edinburgh, in collaboration with the animal genetics company Genus, have produced pigs that are resistant to one of the most costly animal diseases in the […]

June 21, 2018 - 3 minutesmins - By Alexander Burik

Gates Foundation Oxitec Malaria Genetically Modified Mosquitoes

News and Trends 20 Jun 2018

Gates Foundation and Oxitec Fight Malaria with Genetically-Modified Mosquitoes

The Bill & Melinda Gates Foundation has partnered with Oxitec for the development of a new strain of genetically-modified mosquitoes that can help reduce the spread of malaria in America. In its latest effort to free the world of malaria, the Bill & Melinda Gates Foundation has joined forces with Oxitec, a British company that […]

June 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 20 Jun 2018

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […]

June 20, 2018 - 9 minutesmins - By Alexander Burik

News and Trends 15 Jun 2018

London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials

ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […]

June 15, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage

New Blood Test Brings Cheaper Hepatitis B Diagnosis

13 Biotech Leaders You Should Know in the UK’s Golden Triangle

Muscular Dystrophy Drug Fails in Phase 2 Trial

Update: The FDA Approves First Cannabinoid Treatment for Epilepsy

A Biodegradable Plaster Could Help us Treat Mouth Ulcers

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

Next-Generation CAR-T Company Raises €130M on NASDAQ IPO

Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World

Gates Foundation and Oxitec Fight Malaria with Genetically-Modified Mosquitoes

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!